Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There is zero information on that partnership. Zero. You can't model anything based on zero insights.
The total market for these drugs is not Elite's "potential". That is only pure garbage.
Love how SequestOx was the saving grace before and now it's small potatoes - all right around the time the company was focusing on the importance of how well the generic line was doing. Lol It's yuuuuge!
Lower lows and lower highs. Going to continue until real results are achieved...until then it is just another quarter of kicking the can down the road.
Perhaps Nasrat can run for Congress?!
I think it peaked July 2016 with the slam dunk approval remarks and the CEO stating that the FDA can't stop them...
Legal battle will take longer than a year.
Not if the company doesn't partner. Going it alone is strongly being considered...
Does not impact ELTP. A company needs to file with Canada first. Patents are one thing, drug approvals are another...
Wasn't a phony valuation. No respectful organization releases who does the valuation. It was just based on unrealistic expectations, dilution & timeframes at that time.
I agree somewhat. He tells part of the story, but not enough to understand that diplopie clears up. The script is as poorly written as the 8-K's and with Q&A on the fly, there leaves to many gaps.
The CEO gave a low, medium & high end price range prior to SequestOx submission. He used this news to prop up the stock price ahead of his massive dilution. I should do the math to see how the market cap compare then vs now...
The question for DCF purposes depends upon when, if & how. Way too many unknowns with litigation, partnership choice, split % , etc. If they don't partner, the margins will be significantly higher, but have to build a sales force and higher margins on very little sales is a piss poor idea.
That I agree. I think the company is doing the right things to remove it, but I have little trust in the CEO. Open Q&A would help rebuild it.
Market values based on available public knowledge and risks. Goes to show the lack of trust in management to be able to execute.
Funny. Market says otherwise.
And Athenex has how many shares outstanding? Oh, only about 15x less or so, 50M vs Elite's.
Doesn't SequestOx need to be resubmitted for approval? Lol No where close to any sort of resubmission. Company has no idea how to fix issue that led to the 2nd round of crappy BE results.
Funny how CEO had multiple options to run with SequestOx BE testing. Where did those options go, unless going back to square 1 was one of them?
And $10 million suffices for a company that will have one billion shares outstanding?! Wow, way to shoot for sun-mediocrity. Rah rah rah!
Not that far out. I find it fascinating. The funny thing is they aren't the only ones as others are further along and leading the way.
The good news for Elite is that it probably won't be as versatile and plug & play like their tech slowing down full adoption.
I sat next to a woman on a plane a few weeks ago and she spoke to the Phase II trials taking place at a local college on East coast, with whom they partner, for pain killing drugs that are just as effective, but not opiate based - dulls pain without the addiction risk. Still several years out as only in Phase II...
Approval is great news, but Elite hasn't proven that can execute well. That is the missing key ingredient today.
Um no it won't. Depends on how they set up their distribution strategy. The bigger the partner, the better. Their idea of going alone will be yet another disaster for both sales, profit and stock price.
How many millions and millions of shares were dealt out for that? Oh yeah, and revenue will be less than last year.
Clear path forward was before 2nd round of crappy BE results.
There was never a promise of approval from the FDA.
It is disappointing, but little worth worrying about. Current sales are so paltry they cannot be considered as sales so any temporary decrease has no meaning, just as any temp increase has no meaning (e.g., Trimipramine).
Shareholder confidence will increase once SALES start rolling in. They may be near approval, and hopefully is the case, but they can still make some piss poor decisions ahead of them impacting potential revenue.
What? Perc already got a CRL based on the early Sep 8-K.
Front page of company website and they misspell the company's premier drug. Lol
"SquestOx™, for which it received the CRL..."
Stellar attention to detail just like FDA filings.
You just can't make this stuff up.
You can write an essay on the "spike down".
"Spikes 3.9%" Hahahaha!
In reality, it is probably bringing in more rev than Epic's Oxy.
It is yuuuuuuuge!
That is actually pretty funny. Lol
Good thing they had the ability to buy Trimipramine!
When did I say it was all dilution? You have the wrong poster. I don't read all comments on this board as there is too much crap.
Dilution is one of the reasons among many driving the low stock price, but I do not believe the volume is dilution.
Very true and then worth of the company would still be nil.
Lol Dilution is just the start. Self dealing. Leaving out critical details to investors. Where should I stop?
Look at the SEC filings. Dilution has been non stop since Nasrat came on board. Non stop. Including most recent quarter. It slowed down last quarter since SequestOx was on hold, but hasn't come close to stopping, nor will it for a long time.
So is the stock price closer to it's high or it's low? This isn't rocket science. Sitting at 10 cents now with the potential for significant dilution being ignored in your commentary. ANDAs or NDAs filed is one thing. Approval is much different. If approval does happen not pursuing a partner (viable option as CEO mentioned) will decimate this stock price even further. This company is slinging turds against the wall to see what sticks & selling the story to shareholders as if is the best thing since sliced bread. The devil is in the details. Love how the CEO always ignores the most important ones.
Not sure who said that, but much closer to reality than SequestOx slam dunk approval. Lol